Simplex Trading, LLC Inhibrx, Inc. Transaction History

Simplex Trading, LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 Apr 25, 2024	SELL	$32.76 - $39.56 $1.14 Million - $1.37 Million	-34,646 Reduced 96.61%	1,215 $42,000
Q4 2023 Feb 02, 2024	BUY	$14.5 - $38.0 $510,762 - $1.34 Million	35,225 Added 5538.52%	35,861 $1.36 Million
Q3 2023 Nov 01, 2023	BUY	$15.75 - $26.31 $10,017 - $16,733	636 New	636 $11,000
Q2 2022 Aug 03, 2022	SELL	$8.52 - $25.26 $1,320 - $3,915	-155 Reduced 92.81%	12 $0
Q1 2022 May 02, 2022	SELL	$19.89 - $43.18 $219,247 - $475,973	-11,023 Reduced 98.51%	167 $3,000
Q4 2021 Feb 23, 2022	BUY	$26.75 - $46.02 $299,332 - $514,963	11,190 New	11,190 $488,000

25.3K

Ticker INBX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,057,700
Market Cap $617M
Description
Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, and pancreatic adenocarcin...

Get notified when there are updates to the investment portfolio of Simplex Trading, LLC, based on Form 13F filings with the SEC.

Stay updated on Simplex Trading, LLC with notifications on news.